215 related articles for article (PubMed ID: 24797583)
21. High-affinity interleukin 2 receptors on B cell chronic lymphocytic leukemia cells are induced by phorbol myristate acetate but not by calcium ionophore.
Mitsui H; Yagura H; Tamaki T; Ikeda H; Matsumura I; Kanakura Y; Yonezawa T; Tarui S
Immunol Lett; 1991 Feb; 27(2):105-11. PubMed ID: 2026453
[TBL] [Abstract][Full Text] [Related]
22. Diminished DNA synthesis in T cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals.
Prieto A; Garcia-Suarez J; Reyes E; Lapeña P; Hernandez M; Alvarez-Mon M
Exp Hematol; 1993 Nov; 21(12):1563-9. PubMed ID: 8405237
[TBL] [Abstract][Full Text] [Related]
23. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells.
Lotz M; Ranheim E; Kipps TJ
J Exp Med; 1994 Mar; 179(3):999-1004. PubMed ID: 8113691
[TBL] [Abstract][Full Text] [Related]
24. Induction of B-cell chronic lymphocytic leukaemia and hairy cell leukaemia like phenotypes by phorbol ester treatment of normal peripheral blood B-cells.
Visser L; Poppema S
Br J Haematol; 1990 Jul; 75(3):359-65. PubMed ID: 2386770
[TBL] [Abstract][Full Text] [Related]
25. Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets.
Beiske K; Clark EA; Holte H; Ledbetter JA; Smeland EB; Godal T
Int J Cancer; 1988 Oct; 42(4):521-8. PubMed ID: 2459071
[TBL] [Abstract][Full Text] [Related]
26. TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20(+) Antibody-Secreting Cells.
Ghamlouch H; Ouled-Haddou H; Guyart A; Regnier A; Trudel S; Claisse JF; Fuentes V; Royer B; Marolleau JP; Gubler B
Front Immunol; 2014; 5():292. PubMed ID: 24982661
[TBL] [Abstract][Full Text] [Related]
27. Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells.
Fais F; Sellars B; Ghiotto F; Yan XJ; Dono M; Allen SL; Budman D; Dittmar K; Kolitz J; Lichtman SM; Schulman P; Schuster M; Vinciguerra VP; Rai K; Stevenson FK; Gregersen PK; Ferrarini M; Chiorazzi N
J Clin Invest; 1996 Oct; 98(7):1659-66. PubMed ID: 8833916
[TBL] [Abstract][Full Text] [Related]
28. Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.
Hayden RE; Pratt G; Roberts C; Drayson MT; Bunce CM
Leuk Lymphoma; 2012 Apr; 53(4):537-49. PubMed ID: 21812539
[TBL] [Abstract][Full Text] [Related]
29. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity.
Schattner EJ; Mascarenhas J; Reyfman I; Koshy M; Woo C; Friedman SM; Crow MK
Blood; 1998 Apr; 91(8):2689-97. PubMed ID: 9531577
[TBL] [Abstract][Full Text] [Related]
30. Phorbol ester activates CD5+ leukaemic B cells via a T cell-independent mechanism.
Tangye SG; Weston KM; Raison RL
Immunol Cell Biol; 1995 Feb; 73(1):44-51. PubMed ID: 7539402
[TBL] [Abstract][Full Text] [Related]
31. Expression and production of cytokines by heterohybrids and their parental B cells in CLL.
Diaw L; Lefebvre d'Hellencourt C; Cornillet I; Vuillier F; Guenounou M; Dighiero G
Leuk Lymphoma; 1996 Apr; 21(3-4):281-91. PubMed ID: 8726409
[TBL] [Abstract][Full Text] [Related]
32. Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.
Huang PY; Best OG; Almazi JG; Belov L; Davis ZA; Majid A; Dyer MJ; Pascovici D; Mulligan SP; Christopherson RI
Leuk Lymphoma; 2014 Sep; 55(9):2085-92. PubMed ID: 24289109
[TBL] [Abstract][Full Text] [Related]
33. CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells.
Buhmann R; Kurzeder C; Rehklau J; Westhaus D; Bursch S; Hiddemann W; Haferlach T; Hallek M; Schoch C
Br J Haematol; 2002 Sep; 118(4):968-75. PubMed ID: 12199774
[TBL] [Abstract][Full Text] [Related]
34. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.
Chu P; Deforce D; Pedersen IM; Kim Y; Kitada S; Reed JC; Kipps TJ
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3854-9. PubMed ID: 11891278
[TBL] [Abstract][Full Text] [Related]
35. Phorbol ester and B cell-stimulatory factor synergize to induce B-chronic lymphocytic leukemia cells to simultaneous immunoglobulin secretion and DNA synthesis.
Carlsson M; Matsson P; Rosén A; Sundström C; Tötterman TH; Nilsson K
Leukemia; 1988 Nov; 2(11):734-44. PubMed ID: 3263557
[TBL] [Abstract][Full Text] [Related]
36. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents.
Paiva C; Godbersen JC; Berger A; Brown JR; Danilov AV
Cell Death Dis; 2015 Jul; 6(7):e1807. PubMed ID: 26158513
[TBL] [Abstract][Full Text] [Related]
37. Laboratory, morphologic, and immunophenotypic correlates of surface immunoglobulin heavy chain isotype expression in B-cell chronic lymphocytic leukemia.
Shen PU; Fuller SG; Rezuke WN; Sherburne BJ; DiGiuseppe JA
Am J Clin Pathol; 2001 Dec; 116(6):905-12. PubMed ID: 11764081
[TBL] [Abstract][Full Text] [Related]
38. Early gene activation in chronic leukemic B lymphocytes induced toward a plasma cell phenotype.
Segel GB; Woodlock TJ; Xu J; Li L; Felgar RE; Ryan DH; Lichtman MA; Wang N
Blood Cells Mol Dis; 2003; 30(3):277-87. PubMed ID: 12737946
[TBL] [Abstract][Full Text] [Related]
39. Phorbol ester-induced differentiation of chronic B lymphocytic leukaemia cells--regulatory impact of autologous and allogeneic accessory cells.
Danersund A; Tötterman TH; Nilsson K; Egle-Jansson I; Kabelitz D; Sjöberg O
Clin Exp Immunol; 1985 Mar; 59(3):644-52. PubMed ID: 3872753
[TBL] [Abstract][Full Text] [Related]
40. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
